Granted Patent B2

US 12,366,573 · App. 16/597,302 · Granted Jul 22, 2025

Inventor: Robert Karlsson (Uppsala, SE)

Assignee: CYTIVA SWEDEN AB

G01N33/557G01N33/54373G16B30/00

Abstract

Claims (62)

1. A method for evaluation of an interaction between an analyte in a fluid sample and a ligand immobilized on a sensor surface of a biosensor, the method comprising:

providing a reference binding curve, representing a reference interaction for a predetermined acquisition cycle, by acquiring, using the biosensor, one or more binding curves for a reference-analyte ligand interaction at one or more predetermined acquisition conditions;

acquiring, using the biosensor, a sample binding curve for the analyte ligand interaction for the predetermined acquisition cycle including at least one association phase wherein the sensor surface is put into contact with a fluid sample including analyte at a predetermined concentration;

generating a graphical user interface, including an upper threshold curve and a lower threshold curve defined with respect to the reference binding curve, wherein a position of the upper and lower threshold curves is determined by user defined deviation criteria for analysis of the sample binding curve, the at least one of the upper and lower threshold curves movable with respect to the reference binding curve;

identifying a transition between an association phase and a dissociation phase of the predetermined acquisition cycle, the transition including a disturbance of the sample binding curve;

excluding the transition from the sample binding curve;

normalizing the sample binding curve with respect to the reference binding curve based on a binding curve value at a point in the predetermined acquisition cycle before an end of an association phase, the normalizing of the sample binding curve to remove biosensor fluctuation effects;

registering a deviation of the sample binding curve from the reference binding curve according to a threshold range and deviation criteria, the threshold range associated with the upper threshold curve or the lower threshold curve;

classifying the analyte ligand interaction as equivalent to the reference interaction when the registered deviation is less than the deviation criteria;

generating, based on the classification, a determination of molecular binding interaction at a sensing surface independent of interaction models, the determination not including the disturbance associated with the transition between the association phase and the dissociation phase;

displaying, on the graphical user interface, the sample binding curve, including at least one of the upper threshold curve or the lower threshold curve adjustable based on a user-initiated selection via the graphical user interface to move the upper threshold curve or the lower threshold curve with respect to the reference binding curve; and

performing an evaluation based on the at least one of the sample binding curve or the reference binding curve, the evaluation including at least one of a process quality control verification, a fragment screening, an off-rate screening, a thermodynamic screening, a monophasic binder screening, a drug target characterization, or a potency assay evaluation.

2. The method according to claim 1 , wherein the transition between an association phase and a dissociation phase is a disturbance based on known analyte ligand interaction and the one or more predetermined acquisition conditions.

3. The method according to claim 1 , wherein the reference binding curve is provided by acquiring, using the biosensor, one or more binding curves for a reference-analyte ligand interaction at the one or more predetermined acquisition conditions.

4. The method according to claim 3 , wherein two or more binding curves for a reference-analyte ligand interaction are acquired, and wherein the reference binding curve is defined as an average curve or a median curve of said two or more binding curves.

5. The method according to claim 4 , wherein the two or more binding curves are normalized before the average curve or the median curve is provided.

6. The method according to claim 5 , wherein the upper threshold curve and the lower threshold curve are defined by a minimum and a maximum of said two or more binding curves, respectively.

7. The method according to claim 5 , wherein the upper and lower threshold curves are defined by a predetermined standard deviation from the average curve.

8. The method according to claim 1 , wherein the predetermined acquisition cycle includes at least one association phase wherein the sensor surface is put into contact with a fluid sample including analyte at a predetermined concentration.

9. The method according to claim 8 , wherein the predetermined acquisition cycle includes at least two consecutive association phases for different analyte concentrations.

10. The method according to claim 1 , wherein the predetermined acquisition cycle includes at least one dissociation phase wherein the sensor surface is put into contact with a fluid free from analyte.

11. The method according to claim 1 , wherein the sensor surface of the biosensor is provided in a flow cell and wherein the predetermined acquisition cycle defines a flow rate of fluid through the flow cell.

12. The method according to claim 1 , further including:

acquiring, in association with the sample binding curve, a control binding curve for a control-analyte ligand interaction;

registering the deviation of the control binding curve from the reference binding curve; and

verifying an acquisition of the sample binding curve when the deviation of the control binding curve is less than a predetermined control limit.

13. The method according to claim 1 , wherein normalization is based on the binding curve value at a point in the predetermined acquisition cycle before an end of an association phase.

14. The method according to claim 1 , wherein at least one of the ligand and analyte is selected from a group of drug targets and their natural binding partners or reagents used to characterize drug targets.

15. The method according to claim 1 , further including:

displaying on a graphical display, for visual inspection, one or more of:

an overlay plot of the reference binding curve, one or more sample binding curves and optionally the upper threshold curve, the lower threshold curve and a control binding curve;

a deviation plot wherein registered deviation from the reference binding curve is displayed for one or more sample binding curves; and

a reference threshold curve plot wherein one or more sample binding curves are displayed on a reference threshold scale.

16. The method according to claim 15 , further including calculating a percentage of data points of the one or more sample binding curves that are located outside one or more reference threshold curves and wherein the deviation criteria is a maximum percentage of data points allowed to be outside of the one or more reference threshold curves.

17. The method according to claim 15 , further including calculating a sum of squares for a threshold reference binding curve or the one or more sample binding curves, where the threshold reference binding curve or the one or more sample binding curves has first been subtracted, further including using a ratio of the sum of squares as an evaluation criteria.

18. A biosensor system comprising:

memory storing instructions; and

a computer processor to execute the memory storing instructions to:

provide a reference binding curve, representing a reference interaction for a predetermined acquisition cycle, by acquiring one or more binding curves for a reference-analyte ligand interaction at one or more predetermined acquisition conditions;

acquire a sample binding curve for the analyte ligand interaction for the predetermined acquisition cycle including at least one association phase wherein a sensor surface is put into contact with a fluid sample including analyte at a predetermined concentration;

generate a graphical user interface, including an upper threshold curve and a lower threshold curve defined with respect to the reference binding curve, wherein a position of respective upper and lower threshold curves is determined by user defined deviation criteria for analysis of the sample binding curve, the at least one of the upper and lower threshold curves movable with respect to the reference binding curve;

identify a transition between an association phase and a dissociation phase of the predetermined acquisition cycle, the transition including a disturbance of the sample binding curve;

excluding the transition from the sample binding curve;

normalize the sample binding curve with respect to the reference binding curve based on a binding curve value at a point in the predetermined acquisition cycle before an end of an association phase, the normalizing of the sample binding curve to remove biosensor fluctuation effects;

register a deviation of the sample binding curve from the reference binding curve according to a threshold range and deviation criteria, the threshold range associated with the upper threshold curve or the lower threshold curve;

classify the analyte ligand interaction as equivalent to the reference interaction when the registered deviation is less than the deviation criteria;

generate, based on the classification, a determination of molecular binding interaction at a sensing surface independent of interaction models, the determination not including the disturbance associated with the transition between the association phase and the dissociation phase;

display, on the graphical user interface, the sample binding curve, including at least one of the upper threshold curve or the lower threshold curve adjustable based on a user-initiated selection via the graphical user interface to move the upper threshold curve or the lower threshold curve with respect to the reference binding curve; and

perform an evaluation based on the at least one of the sample binding curve or the reference binding curve, the evaluation including at least one of a process quality control verification, a fragment screening, an off-rate screening, a thermodynamic screening, a monophasic binder screening, a drug target characterization, or a potency assay evaluation.

19. The biosensor system of claim 18 , further including a sensor surface in a flow cell, wherein the predetermined acquisition cycle defines a flow rate of fluid through the flow cell.

20. A non-transitory computer readable storage medium comprising a computer program including instructions that, when executed, cause a computer to at least:

provide a reference binding curve, representing a reference interaction for a predetermined acquisition cycle, by acquiring one or more binding curves for a reference-analyte ligand interaction at one or more predetermined acquisition conditions;

acquire a sample binding curve for the analyte ligand interaction for the predetermined acquisition cycle including at least one association phase wherein a sensor surface is put into contact with a fluid sample including analyte at a predetermined concentration;

generate a graphical user interface, including an upper threshold curve and a lower threshold curve defined with respect to the reference binding curve, wherein a position of respective upper and lower threshold curves is determined by user defined deviation criteria for analysis of the sample binding curve, the at least one of the upper and lower threshold curves movable with respect to the reference binding curve;

identify a transition between an association phase and a dissociation phase of the predetermined acquisition cycle, the transition including a disturbance of the sample binding curve;

excluding the transition from the sample binding curve;

normalize the sample binding curve with respect to the reference binding curve based on a binding curve value at a point in the predetermined acquisition cycle before an end of an association phase, the normalizing of the sample binding curve to remove biosensor fluctuation effects;

register a deviation of the sample binding curve from the reference binding curve according to a threshold range and deviation criteria, the threshold range associated with the upper threshold curve or the lower threshold curve;

classify the analyte ligand interaction as equivalent to the reference interaction when the registered deviation is less than the deviation criteria;

generate, based on the classification, a determination of molecular binding interaction at a sensing surface independent of interaction models, the determination not including the disturbance associated with the transition between the association phase and the dissociation phase;

display, on the graphical user interface, the sample binding curve, including at least one of the upper threshold curve or the lower threshold curve adjustable based on a user-initiated selection via the graphical user interface to move the upper threshold curve or the lower threshold curve with respect to the reference binding curve; and

perform an evaluation based on the at least one of the sample binding curve or the reference binding curve, the evaluation including at least one of a process quality control verification, a fragment screening, an off-rate screening, a thermodynamic screening, a monophasic binder screening, a drug target characterization, or a potency assay evaluation.

Assignments (2)

Priority Claims (1)

Continuity (2)

References Cited (58)